The induction of tumor cell differentiation represents an attractive strategy for the treatment of a wide range of malignancies. Differentiation of HL-60 promyelocytic leukemia cells towards neutrophils or monocytes has been shown t o induce apoptotic cell death, which is inhibited by bcl-2 overexpression. However, the role of the bc/-Zgene family during erythroid differentiation of human leukemia cells remains unknown. We found that human erythroleukemia (HEL) and K562, two leukemia cell lines that undergo erythroid differentiation do not express Bcl-2, but express Bcl-XL, a related protein that functions as an inhibitor of apoptosis. Differentiation of HEL or K562 cells with inducers of erythroid differentiation (hemin, retinoic acid, or transforming growth factor-8) was accompanied by progressive cell death and degradation of genomic DNA into oligonucleosomal frag-ELLULAR HOMEOSTASIS in vertebrates is regulated
C by several processes that include cell proliferation, differentiation, and cell death. The demise of cells is often accomplished by apoptosis, also referred to as programmed cell death. Apoptosis is a genetically regulated process that can be induced by a variety of stimuli, which include deprivation of growth factors, signaling via certain surface receptors, treatment with DNA-damaging agents or inhibitors of macromolecular synthesis. I In hematopoietic tissues, the survival of progenitor cells and tumover of mature elements is controlled by apoptosis. For example, apoptosis is coupled to terminal differentiation of myeloid progenitor In the erythroid lineage, the production of red blood cells appears to be regulated through the hormone erythropoietin, which has been shown to maintain the survival of erythroid progenitor cells by inhibiting apopto~is.~.~ Although it is generally thought that hematopoietic survival factors maintain cell survival by inducing the synthesis of cellular proteins capable of repressing the apoptotic mechanism, the signals involved in the regulation of hematopoietic cell survival are still poorly understood. Bcl-2 was the first described member of an expanding family of proteins that regulate apoptosis in vertebrate^.^ Four of these proteins: Bcl-2, Mcl-1, A l , and Bcl-XL are expressed in hematopoietic cells and function as repressors of the apoptotic p r o~e s s .~ Beyond their role in the regulation of hematopoietic cell survival and homeostasis, Bcl-2 family members have been shown to contribute to tumorigenesis by inhibiting apoptotic signals that are generated during the activation of certain oncogenes, such as cmyc or the p53 tumor suppressor gene.7 Moreover, Bcl-2 and Bcl-XL can provide signals that rescue tumor cells from apoptosis induced by chemotherapeutic drugs, implicating these survival proteins in the resistance of cancer cells to chemotherapy. ' Leukemia cell lines such as HL-60 undergo differentiation after treatment with retinoic acid (RA) or phorbol e~ther. ' .~ In this model, treatment of HL-60 promyelocytic leukemia cells with RA or phorbol esther induced neutrophil or macrophage-like cell differentiation, respectively, and resulted in progressive loss of cellular viability and intemucleosomal DNA degradation. This differentiation-induced apoptosis ments. The loss of cellular viability was associated with downregulation of bc/-xL mRNA and protein. In contrast, the levels of Bax, another Bcl-2 family member implicated in apoptosis remained unaltered. Constitutive expression of Bcl-XL by gene transfer inhibited apoptosis triggered by erythroid differentiation of HEL and K562 cells. Yet, BcI-XL did not alter the expression of €-globin, which is induced during erythroid differentiation of HEL and K562 cells, arguing that apoptosis and differentiation can be uncoupled by Bcl-XL. These results indicate that 6cl-X~ acts as an antiapoptosis protein in leukemia cells that undergo erythroid differentiation and that downregulation of bcl-x is a component of the apoptotic response that is coupled t o differentiation in human leukemia cells. 0 1996 b y The American Society of Hematology.
was coupled to downregulation of Bcl-2.4 Because little is known about the regulation of apoptosis in tumor models of erythroid differentiation, we have studied the expression and regulation of Bcl-2 and Bcl-xL in human erythroleukemia (HEL) and K562 human leukemia cells. Exposure of HEL and K562 cells to hemin has been reported to induce erythroid I In addition, erythroid differentiation of HEL cells was found to be associated with decreased cell proliferation and viability8 and increased levels of tissue transglutaminase, a marker of apopt~sis.''.'~ Here, we show that HEL and K562 leukemia cells express Bcl-XL but not Bcl-2. Furthermore, erythroid differentiation of HEL and K562 cells was associated with downregulation of Bcl-XL and activation of apoptosis. Our results also demonstrate that constitutive expression of Bc1-x~ blocks apoptotic death, but not the differentiation process triggered by RA, hemin, or transforming growth factor-p (TGFP 1). These results suggest that apoptosis and erythroid differentiation proceed simultaneously, but can be separated by Bcl-X, in human leukemia cells.
(Seromed Biochrom KG) supplemented with 10% heat-inactivated fetal calf serum (Flow Laboratories, Irvine, CA), nonessential amino acids, 2 mmol/L glutamine, 100 U/mL penicillin, and 100 pg/mL streptomycine. Viability and total cell counts were determined at various times by trypan blue exclusion and counting of at least 200 cells from each individual culture. To induce differentiation, cells were cultured in the presence of 60 pmoVL hemin (Sigma, St Louis, MO); 1 ng/mL TGFPl (GIBCO-BRL, Gaithersburg, MD), or 10 pmol/L RA (Sigma) for various times. Fresh medium containing the differentiation inducers was added to the cultures every 48 to 72 hours.
HEL and K562 cells were transfected by electroporation with the SFFV-Neo expression vector containing the human bcl-xL open reading frame driven by the long terminal repeat of the splenic focus forming virus ( p S F F v -b c l -~~) .~~ As a control, transfection was performed with empty SFFV-Neo plasmid. For transfection, 20 pg of plasmid was linearized with Not I (Pharmacia) and resuspended in Hebs buffer (20 mmol/L HEPES, pH 7.0; 137 mmol/L NaCl; 5 mmol/L KCl; 0.7 mmom Na2P0,H; 6 mmol/L Dextrose). HEL cells (lo') were subjected to electroporation at 300 V, 25 pF and selected by growth in the presence of I .25 mg/mL of G418 (GIBCO). K562 cells (IO7) were electroporated at 400 V, 500 pF and selected in medium containing 650 pg/mL of G418.
Expression of Bcl-X, and Bax was determined by Westem blot analysis as previously described? The amount of protein in cell lysates was quantified by a quantitative Coomassie protein assay (Pierce, Rockford, IL). After separation on a sodium dodecyl sulfate (SDS) 12% polyacrylamide gel, proteins were transferred to nitrocellulose (BioRad, Hercules, CA), blocked with 3% bovine serum albumin (BSA) and incubated with rabbit anti-Bcl-X antiserum (a gift of Dr Craig Thompson, University of Chicago, Chicago, IL) or rabbit anti-Bax (a gift of Dr Brian Leber, McMaster University, Hamilton, Ontario, Canada) and then with goat anti-rabbit IgG conjugated to horseradish peroxidase (Amersham, Arlington Heights, IL). Blots were developed by enhanced chemiluminescence using the ECL kit (Amersham). Expression of Bcl-X and Bcl-2 was also determined by flow cytometric analysis using mouse anti-human B~1 -x '~ or 6C8, a hamster antihuman Bcl-2, monoclonal antibody respectively, followed by biotin-conjugated goat anti-mouse IgG (Sigma) and phycoerythrin (PE)-labeled streptavidin (Cappel, Durham, NC) as described! Mouse Leu-4 (Becton Dickinson, Mountain View, CA) and hamster 3F11 monoclonal antibodies were used as control.
Cells (1 to 3 X lo6) were washed with phosphate-buffered saline (PBS) and pelleted by centrifugation at 200g for 5 minutes. Cell pellets were treated as described prev i o u~l y .~ Briefly, cell pellets were resuspended in lysis buffer containing 0.5% SDS and centrifuged. Supematants were incubated with 0.5 mg/mL proteinase K, extracted with phenol, and ethanol precipitated. Samples were suspended in 15 pL of water containing 0.25 mg/mL RNase A. DNA samples were electrophoresed on a 2% agarose gel and stained with 0.1% ethidium bromide.
Total RNA was prepared by the guanidinium thiocyanate method.I6 To assess mRNA expression, a reverse transcriptase PCR (RT-PCR) method was developed. For the RT reaction, RNA (10 pg) was primed with random hexamer and reverse transcribed with Superscript MMLV reverse transcriptase (BRL) in a 20 p L volume. The generated cDNA was amplified by using primers for human bcl-2 (5'AGATGTCCAGCCAGCTGC-ACCTGAC3' and 5'AGATAGGCACCAGGGTGAGCAAGCT3'); bcl-x ("CGGGCATTCAGTGACCTGAC" and 5'TCAGGAACC-AGCGGTTGAAG), bcr/abl (bcr exon 2, "GGAGCTGCAGAT-GCTGACCAAC3'; ab1 exon 2, 5'TCAGACCCTGAGGCTCAA-AGTC3')I7 and glyceraldehyde-phosphate-dehydrogenase (GAPDH) (*'GGTCTTACTCCTTGGAGGCCATGTG3' and ACCTAACTA- 197 bp (bcr-abl), and 898 bp (GAPDH) were size fractionated onto a 2% agarose gel and stained with ethidium bromide. €-globin mRNA was analyzed by Northern blot using standard procedures.'8 Total RNA ( I 0 pg/lane) was electrophoresed onto a 1 % agarose formaldehyde gels and transferred to a nylon filter. Filters were hybridized with a synthetic oligonucleotide probe from position 238 1 to position 2420 of the €-globin gene sequence" end-labeled with [y"P]ATP (3,000 Ci/mmol) (Amersham). Blots were stripped with 0.1% SDS and rehybridized with an 898-bp PCR fragment of the GAPDH mRNA radiolabeled by random priming with [cr"P]CTP (3,000 Cilmmol).
RESULTS
HEL cells express Bcl-X, but not Bcl-2. The expression of Bel-2 and Bel-X was investigated in HEL and K562, two leukemic cell lines that undergo erythroid differentiation.8-' ' Two species of bcl-x "A, bcl-x, and bcl-x,, that exhibited distinct biological function have been described in the human.14 We, therefore, selected an RT-PCR method to discriminate between the two bcl-x forms. Figure 1A shows that bcl-xL, but not bcl-2 mRNA was expressed in K562 and HEL cells. Expression of the bcl-x, form of bcl-x mRNA was not detected in leukemia cells (data not shown). Flow cytometric analysis showed that HEL and K562 expressed Bcl-X,, but not the Bcl-2 protein (Fig 1B) . In contrast, the promyelocytic cell line HL-60 expressed Bel-2, but hardly any detectable levels of Bel-X protein (Fig 1B) in agreement with previous r e s~l t s .~ As an additional control, the expression of the bcr/abl fusion gene that has been shown to inhibit apoptosis in leukemic cell lines was evaluated.20.2' The bcr/ ab1 RNA was detected in K562, which carries the t(9;22) (q34; q 1 1) chromosomal translocation, the cytogenetic hallmark of CML, but not in HL-60 or HEL cells (Fig 1A) .
Erythroid differentiation of HEL cells is associated with downregulation of bel-x, mRNA and protein. HEL cells can undergo erythroid differentiation in the presence of RA, hemin, or TGFP.8,9,22,23 We next assessed the expression of bcl-xL mRNA in HEL cells by a semiquantitative RT-PCR analysis after treatment with agents that induce erythroid differentiation. As shown in Fig 2A, bcl-xL levels in HELNeo cells remained unaltered after incubation for 3 days with RA, hemin, or TGFP, but were clearly downregulated after 6 days of treatment with RA or after 9 days of treatment with hemin or TGFP. As a control, the levels of GAPDH mRNA remained unchanged throughout the course of treatment with the same agents (Fig 2A) . Western blot analysis showed that treatment with RA for 6 days and hemin or TGFP for 9 days induced downregulation of the Bcl-X, protein, whereas the levels of Bax, another Bel-2 family member remained unaltered (Fig 2B) . In addition, Bcl-Xs a form of Bel-X that promotes apopto~is,'~ was not induced during erythroid differentiation of HEL leukemia cells (data not shown).
Differentiation of HEL cells by erythroid inducers is not
Bcl-X lected by growth in medium containing G418. Figure 3 shows that HEL and K562-Neo cells expressed endogenous Bcl-XL protein, which was increased about eightfold after transfection with the pSFFV-bcl-x, plasmid. Untransfected leukemia cells displayed an identical pattern of Bcl-XL expression as HEL-Neo and K562-Neo cells (data not shown).
To assess whether both HEL-Neo and HEL-Bcl-XL cells could undergo erythroid differentiation, we analyzed the expression of the c-globin mRNA, which has been shown to be increased in response to a number of inducers of erythroid differentiation.**'*' Untreated HEL-Neo and HEL-Bcl-XL cells expressed low levels of €-globin mRNA (Fig 4) . However, treatment with RA, hemin, or TGFD for 3 days resulted in a clear increase in the levels of c-globin mRNA as determined by Northern blot analysis (Fig 4) . To confirm this result, the same mRNA analysis was performed in two different HEL-Bcl-XL clones that yielded the same results as those obtained with the HEL-Bcl-XL bulk cell line (data not
RA Hem TGFP
--- ment (Fig 5) . The viability of HEL-Neo cells was 20%, 48%. and 83% by day 6 of treatment with RA, hemin, and TGFP, respectively. By day 9 of treatment, the viability of HEL cells dropped to 5% (RA), 14% (hemin), and 23% (TGFP). By contrast, this loss of viability was not observed in the HEL-Bcl-XL population. Thus, after treatment with RA, hemin, or TGFP for 9 days, between 72% and 85% of the Bcl- X,-transfected cells remained viable. Even after 15 days of treatment with any of the erythroid differentiation inducers, between 60% and 70% of the HEL-Bcl-XI-cells remained viable. To assess whether apoptosis was associated with loss of cell viability, genomic DNA was isolated from the cells and the pattern of DNA degradation examined by gel electrophoresis. Figure 6 shows that genomic DNA from HEL-Neo cells was degraded into oligonucleosomal fragments after treatment for 9 days with RA, hemin, or TGFD, which is characteristic of apoptotic cell death. In contrast, the genomic DNA from HEL-Bcl-XL cells treated with the same differentiation promoting agents remained unfragmented (Fig 6) . Dose response experiments for RA ( 1 to 20 pmol/ L), hemin ( I 0 to 100 pmol/L), and TGFD (from 0.1 to 2 ng/ mL) showed that differentiation of HEL cells as assessed by the percentage of benzidine-positive cells was always accompanied by loss of cell viability due to apoptosis. Thus, we were unable to separate erythroid differentiation and apoptosis in these leukemia cells.
We also analyzed K562, another leukemic cell line that undergoes erythroid differentiation by treatment with hemin."-" Figure 7A shows that expression of €-globin mRNA was upregulated in both K562-Neo and K565-Bcl-XL cells in response to hemin. Furthermore, the number of benzidine positive cells after treatment with hemin for 6 days was similar in both K562-Neo and K565-Bcl-XL cells (56% 5 4% 17 50 5 6, respectively, mean of three experiments). As we found with HEL cells, expression of endogenous Bcl-XL protein was downregulated in K562 in a time-dependent manner during hemin-induced differentiation (Fig 7D) . In contrast, the levels of Bax in K562 remained unaltered after hemin-induced differentiation (data not shown). The levels of bcl-x,. mRNA also declined in response to hemin, in agreement with the protein results (Fig 7C) . RT-PCR analysis showed that bcl;r, was not induced during erythroid differentiation of K562 cells (data not shown). Downregulation of Bcl-XL in K562 treated with hemin for 12 and 15 days was accompanied by progressive loss of cell viability that was associated with fragmentation of genomic DNA into oligonucleosomal fragments (Fig 7B) . In contrast, constitutive expression of Bcl-XI. in K562 cells inhibited the fragmentation of genomic DNA into oligonucleosomal fragments (Fig 7B) . Thus, erythroid differentiation of both HEL and K562 cells is coupled to apoptosis, which is inhibited by constitutive expression of Bcl-XI..
DISCUSSION
hcl-x is a new member of the hcl-2 family of apoptosis regulatory genes. Two hcl-x cDNAs, hcl-x,. and hcl-x,, have been isolated in the human. Bcl-X,-exhibits remarkable structural homology with BcI-2 and inhibits apoptotic cell death on growth factor withdrawal. Recent studies have reported that Bcl-X immunoreactivity is detected in a wide Hybridization with a GAPDH probe and ribosomal RNA (rRNA) staining with ethidium bromide were used as loading controls. IB) Analysis of DNA fragmentation in K562-Neo (N) and K562-Bcl-XL (B) cells after treatment with hemin for 3 days. DNA fragmentation was monitored by electrophoresis onto a 246 agarose gel and staining with ethidium bromide. IC) Total RNA was purified from K562 cells at the indicated time points and subjected t o semiquantitative RT-PCR analysis with oligonucleotide primers specific for bcl-x. The PCR product of GAPDH was used as a control. After 22 cycles, PCR products were electrophoresed onto a 2% agarose gel and stained with ethidium bromide. (D) K562 cells were permeabilized and labeled with mouse anti-Bcl-X monoclonal antibody (closed graphs) or irrelevant antibody as a background control followed by biotinylated anti-mouse IgG and PE-labeled streptavidin, and analyzed by flow cytometry. The "cut o f f line represents the highest level of background fluorescence obtained with control antibody. The percentage of ceils that were negative for Bcl-X increased from less than 5% (day 0 ) t o 45% (day 12) and 60% (day 15).
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From variety of human and mouse tissues.27 Among the hematopoietic and lymphoid tissues, Bcl-X was expressed in cortical thymocytes, activated lymphocytes, megakaryocytes, erythroid precursors, and differentiating myeloid cells.27 In this report, we have examined the regulation and function of bclx during erythroid differentiation of HEL and K562 leukemia cells. Both HEL and K562 undergo erythroid differentiation after treatment with RA, hemin, or TGFp8-" (and our observations). We found that erythroid differentiation of both HEL and K562 cells led to progressive loss of cell viability by activation of an apoptotic process. Moreover, differentiation of HEL and K562 was associated with diminished expression of bcl-x mRNA and protein. Downregulation of Bcl-X, in HEL and K562 leukemia cells is reminiscent of that observed for Bcl-2 during myeloid differentiation of leukemia cells4 Because deregulated expression of Bcl-XL in HEL and K562 cells inhibited apoptosis that is triggered by differentiation, our results suggest that diminished Bcl-X, plays a role in initiating the apoptotic response. In another study, there was no evidence of apoptosis in HEL cells stimulated with RA. 9 However, in that report, the investigators analyzed DNA degradation during the first 48 hours following RA treatment of HEL cells. In the present study, DNA fragmentation was observed after 6 to 9 days of treatment with RA, hemin, or TGFP.
Treatment of erythroid leukemic cells with RA, hemin, or TGFP is associated with induction of €-globin, which has been used as a marker of erythroid differentiati~n.~~.~~.~~ In contrast to the effect of constitutive expression of Bcl-XL on the apoptotic response of HEL and K562 cells, enforced Bcl-XI, expression did not affect the induction of +globin or the percentage of benzidine positive cells, which are characteristic markers of erythroid differentiation. These results indicate that apoptosis and erythroid differentiation proceed simultaneously, but they can be uncoupled by expression of Bcl-XL. This data is in agreement with that recently reported for HL-60 myeloid leukemic cells in that overexpression of Bcl-2 cells did not affect their maturation, but prevented apoptosis induced by myeloid differentiati~n.'.~ Thus, in both myeloid and erythroid leukemic cells, apoptosis and differentiation events can be separated by Bcl-2 or Bcl-XL. Although the molecular machinery that regulates cell death in the erythroid lineage has yet to be fully elucidated, our results argue that Bcl-XL plays an important role by inhibiting the apoptotic response. The importance of bcl-x for the maintenance of normal hematopoietic cells has been definitively established in mice that are deficient in Bcl-x.'* These animals exhibited extensive apoptosis of immature hematopoietic cells in the embryonic liver and died by day 12 to 13 of development.2K However, it is intriguing that two structurally related proteins such as Bcl-2 and Bcl-XL that exhibit overlapping function are differentially regulated in myeloid and erythroid leukemic cell lines. It is possible that differential expression of two Bcl-2 family members in leukemic cells reflects a different regulation of Bcl-2 and Bcl-XL in the myeloid and erythroid lineages. Both Bcl-2 and Bcl-XL share remarkable structural homology and localize to similar intracellular sites suggesting that they inhibit cell death by a similar biochemical mechanism.' However, it has been recently shown that Bcl-2 and Bcl-X, interact differentially with some intracellular targets in vivo.29 Thus, it is formally possible that Bcl-2 and Bcl-XL differ in their functional ability to prevent cell death in a subtle manner. Consistent with this possibility is the observation that Bcl-X, appears more efficient than Bcl-2 in protecting the immature B-cell line WEHI-23 1 from apoptosis induced by certain chemotherapeutic agent^.^"
In addition to Bcl-2 and Bcl-XL, the BCR-ABL fusion protein has been shown to play a role in protecting leukemic cells (those with t(9;22) (q34; q l 1) chromosomal translocation) from apoptotic cell death.2'.22 Thus, deregulated expression of genes such as bcdabl, bcl-2 or bcl-x may result in an accumulation of leukemic cells by inhibiting apoptosis during tumor development andor contributing to the resistance of cancer cells to apoptosis induced by therapeutic agents. In this regard, it has been recently suggested that deregulated Bcl-XL expression may be involved in resistance to cytotoxic drugs in human U937 clones that escaped death triggered by deoxorubicin and vincristine.j' Future studies will have to elucidate whether approaches aimed at inhibiting the activity of these antiapoptotic genes, either alone, or in combination with agents that induce apoptosis (eg, chemotherapeutic drugs, differentiation inducers) are useful in the treatment of malignant diseases.
